The SEC Approves Filing for MEDEZE Group’s IPO of 268 Million Shares to Be Listed on the Stock Exchange of Thailand (SET), Raising Funds to Expand Hair Follicle Cell Business, Robotic Cell Storage System, and Working Capital to Become a Leading Biotech and Stem Cell Bank in Asia.

Mr. Payupat Mahaphol, Managing Director of Investment Banking at Yuanta Securities (Thailand) Co., Ltd., as the financial advisor for MEDEZE Group Public Company Limited (MEDEZE), revealed that the Securities and Exchange Commission (SEC) has officially accepted the filing request for the initial public offering (IPO) of MEDEZE, along with its prospectus and securities offering details. Currently, MEDEZE has a registered capital of 400 million baht, representing 800 million shares, and plans to list these common shares on the Stock Exchange of Thailand (SET) under the Service/Healthcare sector. The company intends to offer up to 268 million new shares, with a par value of 0.50 baht per share, which accounts for no more than 25.09% of the total issued and paid-up common shares of the company following the offering in SET of SERVICE and HEALTH categories

Dr. Weerapol Khemarangsun, Chief Executive Officer of MEDEZE Group Public Company Limited (MEDEZE), revealed that the company provides services for the analysis, separation, cultivation, and storage of stem cells, as well as the testing of immune cell potential (NK Cells). With over 14 years of continuous experience in the industry, the company offers long-term stem cell storage services using advanced innovations and technology. MEDEZE operates through five subsidiaries, including:

1. Medeze NK Co., Ltd., which provides immune cell (NK Cells) potential testing services.
2. Medeze Cosmeceuticals Co., Ltd., which sells beauty products under the DAA brand and dietary supplements.
3. Medeze Research and Development Co., Ltd., which focuses on experimental research and development in biotechnology.
4. Medeze Treasury Pte. Ltd., an investment company that holds and manages the group’s trademarks.
5. Medeze Group Pte. Ltd., which also focuses on experimental research and development in biotechnology.

The company has high potential in providing services with over 30 liquid nitrogen storage tanks. It has the highest capacity for blood extraction at 2,880 cases per year, tissue extraction at 4,560 cases per year, and the ability to test the potential of NK Cells at 1,920 cases per year. The company has partnerships with 228 hospitals nationwide and has distributors both domestically and internationally, including in Vietnam, Singapore, Myanmar, Indonesia, and Cambodia. It also has a large number of scientists and leading professionals in the biotechnology industry, strengthening its network of doctors in leading hospitals. The company is equipped with a Class 100 cleanroom laboratory, as well as modern equipment and technologies used in stem cell banking, such as liquid nitrogen freezing systems, AutoXpress automatic stem cell separation machines, and Quantum automated stem cell expansion incubators.

The company has gained international trust with its frozen storage standards, accredited by the Association for the Advancement of Blood and Biotherapies (AABB) from the United States. This organization certifies strict operational standards for stem cell banks, in compliance with the international quality system requirements set by the U.S. Food and Drug Administration (U.S. FDA). This certification covers activities related to umbilical cord blood storage, from long-term storage to distribution for patient treatments worldwide. Additionally, the company has been certified for Clean Room Class 100 laboratory standards since 2013 by the National Environmental Balancing Bureau (NEBB) from Germany, ensuring proper control of particle levels, pressure, and temperature within the laboratory.

Following the fundraising, MEDEZE plans to invest in expanding its business in the Hair Follicle Cell Bank by developing hair follicle cell innovations to address customer needs related to hair and scalp issues, which are expected to increase among the aging population. Additionally, the company plans to invest in a Robotic Cell Culture System, an advanced and cutting-edge innovation recognized internationally. This system will enhance the safety of the storage process, reduce human errors, and minimize risks from environmental variables. It will elevate the company's credibility to match leading global operators and attract more customers both domestically and internationally.

In the years 2021-2023, MEDEZE's performance showed total revenues of 446.41 million THB, 595.70 million THB, and 701.81 million THB, respectively. The net profits for the same period were 112.06 million THB, 147.19 million THB, and 239.57 million THB, respectively.